Leading the fight against cancer. Always focused on you.
We deliver personalized treatment you won't get anywhere else, led by a team of world-renowned doctors, specialists, and scientists.
Give today. Impact the care of tomorrow.
Your generosity helps support groundbreaking research, world-class care for patients and their families, and vital education programs to train the next generation of cancer experts.
Changing how the world treats cancer through research
Our scientists pursue every aspect of cancer research — from exploring the fundamental biology of genes and cells, to developing immune-based treatments for cancer, uncovering the causes of metastasis, and more.
Find your life's calling
We're here for a reason: Every day, we're working toward a better future. Whether you're experienced or just starting your career, there's a place for you at MSK.
Let's get started
FDA Approves First Targeted Drug to Treat HER2 Low Breast Cancer: Trastuzumab Deruxtecan (T-DXd)
On August 5, 2022, the FDA approved the first targeted therapy for patients with HER2-low breast cancer that has spread to other parts of the body and is unable to be surgically removed. The drug trastuzumab deruxtecan (T-DXd) was approved based on a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK) breast medical oncologist Shanu Modi.